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210Objective: Transcatheter heart valve (THV) procedures are constantly evolving. We report our experience with
valve-in-valve, valve-in-ring, and direct-view valve-in-native-ring implantation in the mitral position.
Methods: Fourteen patients undergoing THV implantation in the mitral position were included. Clinical and
postoperative data, including echocardiography and further follow-up, were analyzed.
Results: Ten valve-in-valve and 2 valve-in-ring procedures were successfully performed using the transapical
access route. For the third valve-in-ring procedure we used an antegrade left-atrial access via right anterolateral
minithoracotomy. In 1 patient surgical mitral valve replacement was planned. Intraoperatively, the annulus ap-
peared severely calcified and regular implantation of a bioprosthesis was not possible. As a last resort, a 29-mm
Sapien XT valve (Edwards Lifesciences Inc, Irvine, Calif) was implanted under direct view. The initial result
was satisfactory, but on the first postoperative day relevant paravalvular regurgitation occurred. Subsequently,
the valve was fixed to an atrial cuff by 1 running suture. In this series 27-, 29-, and 31-mm bioprostheses and
28- and 30-mm annuloplasty rings were treated with 26- or 29-mm Sapien XT valves. Postoperative echocar-
diography on day 10 and after 6 weeks revealed good prosthesis function in all cases. In 2 valve-in-valve patients
who solely received anticoagulation therapy with acetylsalicylic acid, signs of beginning valve thrombosis
occurred after 8 weeks and 3 months, respectively. During further course, valve function was normalized using
warfarin therapy.
Conclusions: Our results demonstrate feasibility of valve-in-valve and valve-in-ring THV procedures in the
mitral position. Permanent anticoagulation therapy with warfarin seems to be necessary to prevent valve
dysfunction. THV implantation in a calcified native mitral ring for bailout seems not to be reproducible and
thus cannot be recommended. (J Thorac Cardiovasc Surg 2014;147:210-9)The development of transcatheter heart valve (THV) proce-
dures has induced profound changes in the treatment
of valvular heart disease during the past decade.1-4 The
promising results of transcatheter aortic valve
implantation (TAVI) procedures for symptomatic aortic
valve stenosis in selected high-risk patients led to stepwise
expansion of their possible fields of application.1 Beside its
originally designated application, the TAVI concept was
successfully expanded to use in patients with history of pre-
vious cardiac surgery and for the treatment of degenerated
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The Journal of Thoracic and Cardiovascular Surghave described promising results of the valve-in-valve
concept for deteriorated bioprostheses.1-3,6 Since Cheung
and colleagues7 first demonstrated feasibility of mitral
valve-in-valve implantation in a human in 2009, further
studies have likewise praised the transapical approach to
allow direct and coaxial access to the mitral valve.1,2
Those developments allowed the treatment of degenerated
bioprostheses by THV procedures to become an elegant
and viable alternative.1,5 But what about failed valve
repairs in high-risk patients?
Despite excellent results reported for mitral valve repair,
the late recurrence of mitral regurgitation is described in up
to 30% of patients with ischemic mitral regurgitation.8-10
This course may boost the number of high-risk patients
requiring reoperation for failed repair in the near future.
Kempfert and colleagues8 additionally mentioned an asso-
ciation of reoperative mitral valve replacement in this
high-risk subgroup with an increased risk for mortality up
to 30%. The expansion of the valve-in-valve concept to-
ward implantation of a THV into an annuloplasty ring could
be a solution for this high-risk subgroup. Kempfert
and colleagues8 demonstrated feasibility by successful
implantation of a 23-mm Sapien bioprosthesis (Edwardsery c January 2014
Abbreviations and Acronyms
EuroSCORE ¼ European System for Cardiac
Operative Risk
STS ¼ Society of Thoracic Surgeons
TAVI ¼ transcatheter aortic valve
implantation
THV ¼ transcatheter heart valve
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DLifesciences Inc, Irvine, Calif) into a 26-mm Physio annu-
loplasty ring (Edwards Lifesciences Inc, Irvine, Calif) in a
sheep model in 2009. The first in-man implantation of a
THV into a mitral annuloplasty ring was described by de
Weger and colleagues in 2010.11 An additional 2 cases
have been reported since then. First, Hammerstingl and col-
leagues12 described in 2013 implantation of transfemoral
26-mm Sapien XT bioprosthesis (Edwards Lifesciences
Inc, Irvine, Calif) into a failed 30-mm Seguin annuloplasty
ring (St Jude Medical, Saint Paul, Minn). Second, Mazzi-
telli and colleagues13 reported in the same year simulta-
neous antegrade valve-in-ring implantation for both a
failed mitral and tricuspid annuloplasty ring. The implanta-
tion of a transcatheter valve into a native valve ring other
than the aortic valve has not yet been described. Our series
reports 10 successful valve-in-valve procedures in the
mitral position, 3 successful mitral valve-in-ring implanta-
tions, and 1 successful direct-view implantation of a THV
in a severely calcified mitral valve annulus.PATIENTS AND METHODS
Patients and Study Design
Since November 2008 a total of 550 patients have been treated with
catheter-based valve implantations at our institution. We included 14 pa-
tients out of those undergoing a THV procedure in the mitral position.
Ten out of these presented with failing mitral valve bioprostheses and a
further 3 with failed mitral valve repair. One patient presented with severe
mitral valve stenosis and was primarily considered for conventional surgi-
cal mitral valve replacement.
The general decision to perform TAVI was made by an interdisciplinary
heart team consisting of cardiologists and cardiac surgeons. For risk esti-
mation the European System for Cardiac Operative Risk (EuroSCORE)
and EuroSCORE II as well as Society of Thoracic Surgeons (STS) score
were used. Criteria for considering the TAVI approach were older than
age 75 years and at high surgical risk as predicted by the applied scoring
systems or at least presence of contraindications for conventional surgery
like porcelain aorta. The final individual risk assessment ultimately relied
on the clinical judgment of the heart team. Each of the reported cases in our
study was an individual, single-case decision. All patients were at prohib-
itive surgical risk and presented in poor clinical condition with relevant co-
morbidities and general severe frailty.
Mean patient age was 75  5 years. The patients were predominantly
women (n ¼ 8; 61.5%). Calculated STS score and EuroSCORE predicted
high surgical risk. Mean logistic EuroSCORE for mortality was calculated
with 54.70%  19.51% and STS score averaged 11.59%  3.10%.
Pre-, intra-, and postoperative data were prospectively collected.
Follow-up included direct interview of patients during ambulant reassess-
ment at our institution. The follow-up was complete, ranging from 34 toThe Journal of Thoracic and Ca220 days with an average of 104  69 days. The complete follow-up con-
formed a total of 34.4 patient-months.
The study was reviewed and approved by the institutional review board
at Medical Faculty ‘‘Carl Gustav Carus’’ at Technical University of Dres-
den, Dresden, Germany (EK No. 53022010). Written informed consent
regarding the off-label use of the Sapien valve was obtained from patients.
Statistical Analysis
Statistical analysis was performed with JMP 9.0 software (SAS Institute
Inc, Cary, NC).2,3 Numeric variables are expressed as means  standard
error of mean or median with interquartile range due to the limited
number of cases.2,3 If applicable, means were compared by the Student t
test.2,3
Setting, Access Routes, and Implantation Technique
THV procedures were performed in a specially equipped hybrid oper-
ating room by an interdisciplinary heart team consisting of cardiac sur-
geons, cardiologists, and cardiac anesthesiologists. For all procedures the
reverse-crimped Sapien XT porcine valve was used, 26-mm THVs were
delivered using the 24F-Ascendra-II delivery system (Edwards Lifescien-
ces, Irvine, Calif) and 29-mm THVs were delivered using the 33F-Ascen-
dra delivery system (Edwards Lifesciences, Irvine, Calif). Prior balloon
valvuloplasty of the degenerated bioprosthesis or failing repair was not per-
formed. As previously reported, stepwise fluoroscopy was performed
throughout the procedure without use of a contrast agent.2,3
Subsequently, prosthesis function was evaluated by transesophageal
echocardiography.2,3
The following access route was used, as previously reported: standard
transapical approach by left-anterolateral minithoracotomy.2,3 This
access route was applied in all 10 patients receiving valve-in-valve implan-
tations and 2 out of 3 patients receiving valve-in-ring TAVI. Valve-in-valve
procedures were performed as previously reported2: right-anterolateral
minithoracotomy using a left atrial access in 1 patient receiving valve-in-
ring TAVI. Finally, median sternotomy was applied in 1 patient undergoing
planned on-pumpmitral valve replacement. The surgery was primarily per-
formed using trans-septal access. Subsequent to failed surgical mitral valve
replacement the THV was implanted under direct view.
Sizing of the THV
Sizing of the valve depended on the type of prior and actual surgery.
Valve-in-valve procedures. As shown in Figure 1, in patients with
prior mitral valve replacement 26- and 29-mm Sapien THVs were
used. Before implantation, the diameter of the degenerated bio-
prosthesis—ranging from 27 to 31 mm—was determined by transesopha-
geal echocardiography. Besides the echocardiographically determined
internal diameter, the internal diameter of the bioprosthesis provided by
the manufacturer was used as the key parameter for valve sizing. As pro-
posed, a 26-mm THV was used for diameters ranging from 21.5 to 24.5
mm and a 29-mm THV for diameters exceeding 24.5 mm. As previously
reported, we occasionally observed a discrepancy between the internal
diameter provided by the manufacturer and the measured diameter.2,3
Calcification or pannus formation were most likely supposed to be
causative for the observed discrepancies. In those cases we relied on the
manufacturer’s information and tended to use the larger THV.
Valve-in-ring procedures. Previously in-human implantation ex-
vivo trials were performed using different annuloplasty rings and THVs
(see Figure 2). In our series solely 29-mm Sapien XT bioprostheses were
used for valve-in-ring procedures. The patients experiencing failed mitral
valve repair presented with Physio annuloplasty rings with sizes 28 and
30 mm. For determination of the estimated internal diameter of the circu-
larized annuloplasty ring after the implantation procedures, the internal
ring area—as provided by the manufacturer—was used. We assumed that
the extent of the circularized annuloplasty ring is defined and would notrdiovascular Surgery c Volume 147, Number 1 211
FIGURE 1. Mitral valve-in-valve procedure. The radiopaque markers of the degenerated bioprosthesis clearly indicate the landing zone and thus easy and
orthograde positioning of the transcatheter heart valve. A, Positioning of the valve before inflation of the balloon. B and C, Gradual inflation of the balloon.
D, Final result.
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absolute ring area must stay the same after THV implantation. Based
on these considerations we calculated the estimated internal diameter
emanating from the known ring area using the formula:
Area ¼ p 3 (diameter 3 ½)2, converted to diameter ¼ 2 3 O(area/p).
Figure 3 demonstrates sizing considerations.
Valve-in-native-ring procedure. As shown in Figure 4, in this
single case the severely calcified mitral annulus could not be passed by a
23-mm measurement device. For safety reasons the THV was oversized
and a 29-mm Sapien XT bioprosthesis was chosen. The THV was
implanted under direct view.RESULTS
Clinical Baseline Characteristics
Patients selected for transcatheter valve-in-valve or
valve-in-ring procedures were characterized by a high
incidence of comorbidities and their high surgical risk.
Preoperatively performed coronary angiography revealed
presence of coronary artery disease in 8 patients. In 4
patients, coronary artery disease had previously been
treated several weeks before by percutaneous coronary212 The Journal of Thoracic and Cardiovascular Surgintervention by means of a staged-hybrid approach. One
patient presented with still-running bypasses after coronary
artery bypass grafting and the remaining 3 patients had no
hemodynamically relevant stenosis. Because the mitral
valve was the leading pathology in all patients who were
once considered unsuitable for conventional surgery due
to their prohibitive surgical risk, TAVI was considered as
a compromise solution, with a clear understanding that
concomitant tricuspid disease must remain unaddressed.
Preoperative clinical baseline characteristics of the TAVI
candidates are summarized in Table 1. One additional
61-year old woman who was initially planned for
conventional mitral valve replacement presented with a
severely calcified mitral valve causing high-grade
stenosis accompanied by severe pulmonary hypertension
(right ventricular end-systolic pressure 100 mm Hg).
This patient also had history of alcohol abuse, toxic
hepatic cirrhosis, and recurrent gastrointestinal bleeding.
Preoperatively, active endocarditis was ruled out by
echocardiography and lab findings in all patients.ery c January 2014
FIGURE 2. Mitral valve-in-ring procedure. A centered position of the transcatheter heart valve with equal proportions in the left ventricle and in the atrium
is advocated to prevent outflow tract obstruction, paravalvular leakage, or valve embolization.
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Two patients presented with a high-grade stenosis of the
mitral bioprostheses with a remaining orifice area of 0.25
and 1.1 cm2. All remaining 8 valve-in-valve patients had
a failing mitral bioprosthesis resulting in severe mitral
regurgitation. Mechanisms of failure were leaflet prolapse
(n ¼ 6) and leaflet perforation (n ¼ 2). Valve-in-ring pa-
tients all presented with a failed repair resulting in a severe
regurgitation. The valve-in-native ring patients presented
with high-grade mitral valve stenosis with a mean trans-
valvular pressure gradient rising to 17 mmHg. Left ventric-
ular ejection fraction averaged 44.5%  17.4%, ranging
from 15% to 65%. All patients presented with a concomi-
tant moderate (n ¼ 7) or severe tricuspid regurgitation
(n ¼ 6) and significant pulmonary hypertension exceeding
60 mm Hg.
Procedural Data
AllTAVI procedureswere primarily successfulwithout any
procedural complications. Intraoperative echocardiographyThe Journal of Thoracic and Carevealed good prosthesis function without relevant para- or
transvalvular regurgitation. Mean procedure time of TAVI
was 51.1  7.4 minutes. A standard transapical access route
was used in all valve-in-valve (n ¼ 10) and in 2 valve-in-
ring procedures. Because of hostile chest configuration, the
remaining valve-in-ring procedure was performed using an
antegrade left-atrial access by right-anterolateral
minithoracotomy.
A 26-mm Sapien XT bioprosthesis was implanted in
failing Hancock II (Medtronic, Minneapolis, Minn) 27-
mm valves (n ¼ 1) and 29-mm valves (n ¼ 3), and Sapient
XT porcine 27-mm bioprostheses (n¼ 1). For Hancock 31-
mm (n ¼ 1), Hancock II 31-mm (n ¼ 2), Perimount 29-mm
(Edwards Lifesciences, Irvine, Calif) (n ¼ 1), and Shelhigh
31-mm bioprostheses (Shelhigh Inc, Union, NJ) (n ¼ 1), a
29-mm Sapien XT THV was used. The valve-in-ring pa-
tients presented with failing Physio annuloplasty rings
with sizes 28 mm (n ¼ 1) and 30 mm (n ¼2). In all
valve-in-ring procedures a 29-mm Sapien XT THV was
implanted.rdiovascular Surgery c Volume 147, Number 1 213
FIGURE 3. Sizing considerations for valve-in-ring procedures.
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replacement by median sternotomy. During the procedure,
the mitral valve presented as being severely calcified with
extensive calcifications infiltrating the ventricular muscle.
The remaining orifice area could not be passed with a 23-
mm measurement device and pledged valve sutures could
not be placed because of the extensive calcifications. For
bailout, direct-view implantation of a 29-mm Sapien XT
bioprosthesis was performed. This patient was transmitted
to our intensive care unit under intra-aortic balloon pump
and catecholamine support. On postoperative day 1 trans-
esophageal echocardiography demonstrated progressive
paravalvular regurgitation. For those reasons a second-
look procedure was performed. During this procedure,
the scaffold of the Sapien valve was fixed to an atrial
cuff using 1 running 3-0 polypropylene suture
(Figure 4). Weaning from extracorporal circulation was
problem-free and echocardiography revealed good pros-
thesis function with only mild remaining paravalvular
regurgitation and a peak/mean transvalvular pressure
gradient of 7/2 mm Hg.FIGURE 4. Postoperative aspect after the second look procedure. The
transcatheter heart valve is implanted in the native calcified mitral annulus
and secured with a running 3-0 polypropylene suture to an atrial cuff.Postoperative Data
Postoperative course was mainly uneventful. Our main
clinical endpoints are summarized according the Valve Ac-
ademic Research Consortium-2 criteria in Table 2. No im-
mediate procedural mortality within the first 72 hours was
observed. During primary hospital stay a total of 2 patients
died (15.4%). One patient from the valve-in-valve group
died from pneumonia on day 34 and 1 valve-in-native-
ring patient died after prolonged intensive care unit stay
from massive upper gastrointestinal bleeding on day 41.214 The Journal of Thoracic and Cardiovascular SurgSeven patients (53.8%) experienced postoperative renal
injury according Acute Kidney Injury criteria, but only 1
patient needed hemofiltration. During primary hospital
stay and further follow-up neither myocardial infarction
nor stroke, bleeding, or access-site complications were
observed. One patient from the valve-in-valve-group
needed permanent pacemaker implantation due to brady-
cardic atrial fibrillation. In summary, the hospital course
and further follow-up was uneventful in all TAVI patients.
On the contrary, the valve-in-native-ring patient experi-
enced a prolonged intensive care unit stay with high-dose
catecholamine and intra-aortic balloon pump support as
well as long-time ventilation and disturbed wound healing,
finally dying from gastrointestinal bleeding.ery c January 2014
TABLE 1. Clinical baseline characteristics (only transcatheter aortic
valve implantation candidates [n ¼ 13])
Characteristic Result
Age, y 75.0  5.0
Men 6 (46.2)
European System for Cardiac Operative
Risk Evaluation (%)
54.70  19.51
Society of Thoracic Surgeons score (%) 11.59  3.10
Body mass index 24.6  4.6
New York Heart Association functional class III 13 (100.0)
Left ventricular ejection fraction (%) 44.5  17.4
Pulmonary hypertension>60 mm Hg 13 (100.0)
Atrial fibrillation 6 (46.2)
Permanent pacemaker 4 (30.8)
Arterial hypertension 12 (92.3)
Type 2 diabetes mellitus 8 (61.5)
Dietary 2 (25.0)
Oral 2 (25.0)
Insulin 4 (50.0)
Chronic renal failure 8 (61.5)
Preoperative creatinine, mmol/L 107  46
Coronary artery disease 8 (61.5)
Chronic obstructive pulmonary disease 3 (23.1)
Extracardiac arteriopathy 4 (30.8)
History of stroke 3 (23.1)
History of previous cardiac surgery
Isolated mitral valve replacement 9 (69.2)
Isolated mitral valve repair 2 (15.4)
Combined coronary artery bypass graft, mitral
or tricuspid valve repair
1 (7.7)
Combined mitral or aortic valve replacement 1 (7.7)
Time interval to previous surgery, y 8.1  3.1
Values are presented as mean  standard deviation or n (%).
TABLE 2. Clinical endpoints according to Valve Academic Research
Consortium-2 criteria* in all patients (n ¼ 14)
Endpoint Result
Procedural success (valve-in-valve/valve-in-ring) 13 (100.0)
Mean procedure time (valve-in-valve/valve-in-ring), min 51.1  7.4
Immediate procedural mortality (<72 h after the
procedure)
0
Procedural mortality (primary hospital stay) 2 (15.4)
Pneumonia on day 34 1
Fatal upper gastrointestinal bleeding on day 41 1
Mortality during further follow-up 0
Myocardial infarction 0
Bleeding complications 0
Vascular access site and access-related complications 0
Acute kidney injury classification 7 (53.8)
Renal failure (continuous veno-venous hemofiltration) 1
Stroke and transient ischemic attack 0
Conduction disturbances and arrhythmias 2 (15.4)
New onset atrial fibrillation 1
Permanent pacemaker implantation (bradycardic atrial
fibrillation)
1
Other transcatheter aortic valve implantation-related
complications
1
Rethoracotomy 1 (7.7)
Second-look for reanchoring the direct-view implanted
transcatheter heart valve
1
Hospital stay, d 13.2  11.3
Follow-up time, d 104  69
Echocardiographic results for valve-in-valve-procedures
No valvular regurgitation 9 (90.0)
Trace transvalvular regurgitation 1 (10.0)
Peak pressure gradient, mm Hg 15.3  5.5
Mean pressure gradient, mm Hg 6.2  2.6
Echocardiographic results for valve-in-ring-procedures
Trace transvalvular regurgitation 2 (66.7)
Mild transvalvular regurgitation 1 (33.3)
Peak pressure gradient, mm Hg 13.5  0.7
Mean pressure gradient, mm Hg 6.0  1.4
Echocardiographic result for valve-in-native-ring-
procedure (final result)
Mild paravalvular regurgitation 1
Transvalvular pressure gradient dPmax/mean, mm Hg 7/2
Values are presented as mean standard deviation, n (%), or n. *FromKappetein AP,
Head SJ, Genereux P, Piazza N, van Mieghem NM, Blackstone EH, et al. Updated
standardized endpoint definitions for transcatheter aortic valve implantation: the
Valve Academic Research Consortium-2 consensus document. J Thorac Cardiovasc
Surg. 2013;145:6-23.
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demonstrated good hemodynamics and good prosthesis
function in all 14 patients. Most patients (9 out of 10)
from the valve-in-valve group showed no valvular regurgi-
tation with only 1 patient having trace transvalvular regur-
gitation. Likewise, the valve-in-ring patients only showed
trace regurgitation in 2 patients and mild transvalvular
regurgitation in 1 patient. Measured transvalvular pressure
gradients significantly decreased in all patients and revealed
excellent prosthesis function (Table 2). In 2 valve-in-valve
patients who received anticoagulation therapy solely with
100 mg acetylsalicylic acid per day, signs of beginning
valve thrombosis occurred after 8 weeks and 3 months,
respectively. They presented with increasing transvalvular
pressure gradients and thickened valve leaflets. Endocardi-
tis was ruled out by lab testing. The findings were inter-
preted as beginning valve thrombosis. For those reasons
oral anticoagulation therapy with warfarin with a target in-
ternational normalized ratio of 2.5 was initiated. During
further course, the previously described echocardiographic
findings were completely regressive and transvalvular pres-
sure gradients decreased.The Journal of Thoracic and CaDISCUSSION
The development and implementation of transcatheter
heart valve procedures has induced profound changes in the
treatment of valvular heart disease.1-3 At the same time, in
conventional cardiac surgery a trend toward more frequent
use of biologic substitutes instead of mechanical heart
valves can be observed, potentially leading to an increasing
number of patients presenting with deteriorated
bioprosthesis in the near future.14 Additionally, mitral valve
repair has been demonstrated to be superior for patientsrdiovascular Surgery c Volume 147, Number 1 215
FIGURE 5. Mitral valve-in-valve procedure in a patient with history of
previous aortic and mitral valve replacement. The projection of both bio-
prostheses over each other made the procedure more demanding. In the
end the presence of aortic bioprosthesis was not a drawback.
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Dwithmitral regurgitation in general and ischemicmitral regur-
gitation in particular.8 Nonetheless, there is a high rate of
ischemic mitral regurgitation recurrence after valve repair.8
Increasing life expectancy and those described developments
will raise the absolute number of patients with degenerated
bioprostheses or failed mitral valve repair needing repeat
mitral valve surgery in the near future. However, redo
procedures, especially in elderly and high-risk patients, are
still affected by increased perioperative risk up to 20%.1,15-17
Our success in highest-risk patients and encouraging re-
sults of TAVI in general progressively expand the potential
scopes of application to now include patients with previous
cardiac surgery and failed bioprostheses or mitral valve
repair in particular.1-3,5,8,13
Our study included 3 different entities of further evolutions
in THV procedures: valve-in-valve, valve-in-ring, and valve-
in-native-ring, which have to be discussed separately.
Transcatheter Mitral Valve-in-Valve Implantation
The first description of the valve-in-valve concept for
failed aortic bioprosthesis by Walther and colleagues in
200718 heralded a new era of catheter-based valve therapies.
Since then multiple studies have demonstrated the safety
and feasibility of aortic valve-in-valve therapies.1 In 2008
Kempfert and colleagues19 adapted the aortic valve-in-
valve concept for mitral bioprostheses in a sheep model
and not that much later, in 2009, Cheung and colleagues7
first performed a mitral valve-in-valve procedure in a
human. Since that time, valve-in-valve procedures have
progressively advanced to being considered a viable and
elegant alternative in selected highest-risk patients.1,20
A main concern is the exact determination of the internal
diameter of the degenerated bioprosthesis.1 Because of
nonstandardized methodologies for labeling valve sizes,
the labeled sizes usually do not reflect the real internal
diameter.1 The internal diameter needs to be carefully
determined by echocardiography and set in relation to the
internal diameter given by the manufacturer.1,2 In our
series we observed a significant discrepancy between
these.2 This discrepancy might be caused by calcification
or pannus formation of the biologic substitute.1,2 It has to
be assumed that the expansion of the transcatheter valve
is mainly impeded by the sewing ring and calcifications
additionally might ease during valve expansion. Thus it
seems to be justified to rely on the internal diameter of
the biologic substitute given by the manufacturer.1,2 For
secure anchoring, a moderate oversizing of the
transcatheter valve exactly matching or exceeding the
internal diameter of the degenerated bioprosthesis is
advocated by most groups.1,2,14,21 It has to be kept in
mind that excessive oversizing might impair leaflet
opening and thus promote early valve degeneration,
whereas significant underexpansion might venture
paravalvular leakage or valve migration.1216 The Journal of Thoracic and Cardiovascular SurgIn linewith other series, our experiencewith transcatheter
mitral valve-in-valve implantations did not reveal anyproce-
dural problem.2,14,21 The transapical approach allowed a
direct and coaxial access to the mitral valve.2 Herein, the
degenerated bioprosthesis and its radiolucent markers
allowed exact and easy-to-perform orthograde positioning
of the transcatheter valve.2 In particular, patients with
history of previous aortic and mitral valve replacement has
to be mentioned. After initial concerns that the aortic
bioprosthesis might impair placement of the THV in the
mitral position or even could get damaged, the procedure
fortunately was uncomplicated. Projection of the valves
over each other during angiography made THV positioning
a little more demanding (Figure 5). In the end, the presence
of aortic bioprosthesis was no drawback and the procedure
was as convenient to perform as the other valve-in-valve
procedures. In contrast to TAVI procedures in general or
valve-in-valve procedures for failed aortic bioprostheses,
mitral-valve-in-valve TAVI needs no administration of
contrast agent.2 In line with other series, all patients in our
study demonstrated excellent postprocedural echocardio-
graphic results and experienced a significant reduction of
preoperative mitral regurgitation to grade 0 or 1.2,14,21 The
observed short procedure times reflect the straightforward
character of the procedure. Such short procedure times are
less consuming for the patient and the operating surgeon,
as well.2 Additionally, the risk of trauma to cardiac struc-
tures or patent bypass grafts is minimized in comparison
to complex conventional redo procedures. An interestingery c January 2014
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lation was solely achieved with acetylsalicylic acid therapy
developed beginning valve thrombosis within several weeks
after the procedure. Maybe there exist low-flow areas
between the stent-scaffold of the THV and the struts of the
bioprosthesis that promote thrombosis. The modification
of the anticoagulation regimen to permanent warfarin ther-
apy led to a complete regression of the beginning valve
thrombosis. These observations suggest that sole therapy
with acetylsalicylic acid is not sufficient in cases of mitral
valve-in-valve THV. Summing up, the simplicity of
positioning the valve, guided by radiolucent markers of the
degenerated bioprosthesis, and the direct and coaxial access
as provided by the transapical approach, make valve-in-
valve TAVI for degenerated mitral bioprostheses as
convenient to perform as a penalty kick without goal keeper.
Permanent warfarin therapy should routinely be initiated.
Transcatheter Mitral Valve-in-Ring Procedures
Far less is known about valve-in-ring procedures. The
initial idea was developed by Kempfert and colleagues,8
who reported in 2009 successful mitral valve-in-ring
TAVI using an antegrade transatrial approach. For those
purposes, they unexceptionally used 26-mm Physio annulo-
plasty rings and 23-mm Sapien transcatheter valves.8 The
procedure itself was successful in all sheep and provided
acceptable hemodynamic results, ranging from no paravalv-
ular leakage (n ¼ 1) to mild (n ¼ 5) and moderate leakage
(n ¼ 1).8 Not that much later, in 2011, de Weger and col-
leagues11 reported the first successful valve-in-ring TAVI
in a human using a transapical approach. They described
successful implantation of a 26-mm Sapien transcatheter
valve in a 28-mm Physio annuloplasty ring in a 72-year
old man with history of prior combined mitral valve repair
and coronary artery bypass graft 8 years ago.11 Double
mitral and tricuspid valve-in-ring implantation was recently
reported by Mazzitelli and colleagues in 2013.12 Using a
transatrial antegrade approach, Mazzitelli and colleagues13
described implantation of a 26-mm Sapien bioprosthesis in
both a 28-mm Physio mitral ring and 26-mm Classic (Ed-
wards Lifesciences, Irvine, Calif) tricuspid ring during 1
procedure. Predischarge echocardiography showed good
prosthesis function.12 The most recently reported case was
published by Hammerstingl and colleagues in early
2013.13 They described transfemoral implantation of a
26-mm Sapien XT transcatheter valve in a 30-mm Seguin
annuloplasty ring.13 The procedure was uneventful and
postoperative echocardiography revealed an excellent
hemodynamic result.13
Until today, there existed besides the reported animal
model only 3 case reports.8,11-13 Our series summarizes 3
consecutive cases of mitral valve-in-ring TAVI procedures
at our institution. Two of the procedures were performed us-
ing the transapical approach, which has meanwhile becomeThe Journal of Thoracic and Caa convenient standard access route. In line with the above-
mentioned advantages of transapical access for mitral
valve-in-valve procedures, valve-in-ring TAVI likewise
benefits from the direct and coaxial access as provided by
transapical access route. In the remaining patient with a
so-called hostile chest we opted for an antegrade left-
atrial access using a right-anterolateral minithoracotomy.
This approach was quite challenging because it did not pro-
vide a coaxial access to the mitral annulus. The length of the
delivery device and the angle of the mitral axis made it diffi-
cult to align the THV in an orthograde position. Finally, the
procedure was—despite technically challenging aspects, as
the 95-minute procedure time reflects—uneventful and the
hemodynamic result was excellent. In contrast, the transap-
ical valve-in-ring procedure lasted only about 55 minutes in
both cases.
Sizing of the valve and determination of the inner diam-
eter is essential in valve-in-ring procedures. Exact determi-
nation of the final internal diameter of the annuloplasty ring
might be the most challenging aspect of the procedure. In
contrast to valve-in-valve procedures, echocardiography
and computed tomography are useless for measurements
in this context. The shape of an annuloplasty ring and its di-
mensions before implantation are completely contrary to
the shape and dimensions of the circularized annuloplasty
ring after THV implantation. In line with other study groups
we first proofed different combinations of annuloplasty
ring and THV before implantation in an ex-vivo model,13
but additionally calculated the estimated postimplantation
internal diameter. For approximation of the internal
diameter we used the ring area as provided by the manufac-
turer. Assuming that the ring area and the circumference
must stay constant even after THV implantation, it is
possible to calculate the estimated diameter of the circular-
ized annuloplasty ring using the circle formula
(Area ¼ p 3 (diameter 3 ½)2). The internal diameter so
created provides a sufficient lead for sizing the THV. Unfor-
tunately, annuloplasty rings are semirigid and implantation
of a THV will not be able to totally reshape and circularize
the ring—as demonstrated by our ex-vivo trials. Especially
in the area of the commissures, a small gap remained be-
tween ring and THV. Surprisingly, these gaps seem to be
meaningless in in-vivo implantations. It has to be assumed
that surrounding valvular tissue or pannus formation seals
these gaps. We observed no paravalvular leakages at those
gap areas. All valve-in-ring procedures of our series pro-
vided excellent hemodynamic results and good prosthesis
function. In our series, we successfully used 29-mm Sapien
XT valves for 28-mm and 30-mm Physio annuloplasty
rings.
Accordingly, for valve-in-valve procedures, the radi-
opaque markers of the annuloplasty ring clearly
indicate the landing zone and the procedure usually can
be performed without administration of contrast agent.11rdiovascular Surgery c Volume 147, Number 1 217
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the upper pulmonary vein, which provides a favorable angle
to the mitral valve. Finally, it has to be mentioned that exact
positioning of the THV is of utmost importance. We advo-
cate a centered position of the THV in the mitral annulus
with equal proportions within the left atrium and the
ventricle (Figure 2). This is in line with de Weger and col-
leagues.11 Positioning of the THV more toward the
ventricle might cause outflow tract obstruction by the
THV itself or the displaced anterior mitral leaflet. On the
contrary, positioning more toward the left atriummight pro-
mote paravalvular leakage or even valve embolization dur-
ing systole. Summing up, valve-in-ring procedures are
feasible, providing excellent hemodynamic results, but are
burdened with some technically challenging aspects like
sizing and imponderables like durability. As of today,
including our series, only 6 cases are published worldwide.
Thus, much more data is needed to provide a final statement
on this developing but promising technique.
Mitral Valve-in-Native-Ring Procedure
A comparable procedure has not been reported until
today. In our patient presenting with a severe mitral valve
stenosis a surgical valve replacement was planned. Intrao-
peratively the mitral annulus presented severely calcified
with extensive calcifications deeply infiltrating the ventric-
ular muscle. Valve sutures could not be placed and the
annulus could not be passed with a 23-mmmeasurement de-
vice. For those reasons we decided for direct-view implan-
tation of a 29-mm Sapien XT valve into the native mitral
annulus. Due to its severe calcification, the native annulus
initially allowed somewhat secure anchoring of the valve.
On first postoperative day we had to perform a second-
look procedure because of incipient valve dislocation and
paravalvular leakage. During this procedure, the THV stent
was fixed by a running 3-0 polypropylene suture to an atrial
cuff (Figure 4). Afterward, echocardiography revealed
constantly good prosthesis function without paravalvular
leakage. The patient died after prolonged intensive care
unit stay on postoperative day 41 from massive upper
gastrointestinal bleeding. Nonetheless, this case demon-
strated that valve-in-native ring procedures are not really
feasible. In this absolute bailout situation it worked once,
but can surely not be recommended. With the presently
available devices, valve-in-native-ring procedure seems
not to be reproducibly possible.
Study Limitations
Our study was mainly limited by the number of patients
studied. Our main focus was on technical aspects and to
demonstrate feasibility of the described procedures. The
final value of the procedures cannot be determined until
much more data are available. Additionally, it has to be
kept in mind that despite the euphoria concerning218 The Journal of Thoracic and Cardiovascular Surgcatheter-based heart valve procedures, conventional surgery
still remains the gold standard and provides excellent
results. The reported techniques, which are stringent
off-label use of THVs, are geared toward individually
selected patients at prohibitive surgical risk, which always
must remain an individual assessment.CONCLUSIONS
For mitral valve-in-valve or valve-in-ring procedures for
access, the transapical approach and the antegrade left-atrial
approach are feasible. The transapical approach, which
provides direct and coaxial access, is far more convenient
and easy to perform. Valve-in-valve procedures have
nearly advanced to being standard procedure in selected
highest-risk patients with prohibitive surgical risk.
Valve-in-ring procedures are feasible, but much more data
are needed to provide a final statement. Both techniques
can be seen as complementary surgical techniques for
tailor-made and patient-oriented surgery in the near
future. Finally, valve-in-native ring procedure seems to
be possible in defined anatomic requirements in an
ultima ratio bailout situation, but cannot generally be
recommended.References
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